Overview

Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Phase II trial to explore the efficacy of vorinostat and tamoxifen combined.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Estrogens
Selective Estrogen Receptor Modulators
Tamoxifen
Vorinostat